Search Results

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration RoslinCT will manufacture world’s-first CRISPR-based therapy.

RoslinCT to manufacture first-ever US FDA approved CRISPR-based gene therapy CASGEVY™ (exagamglogene autotemcel).

RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene Therapies, is pleased to announce the appointment of Dean J. Morris as the Chief Operations Officer at their Boston facility.

RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene therapies, announced the appointment of Derek Hei, Ph.D., to its Scientific Advisory Board (SAB).

RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, announce their integration, creating a unified business that will operate under the RoslinCT brand.

RoslinCT and Lykan Bioscience, a leader in Contract Development and Manufacturing for cell therapies, announced the appointment of Michael Mendicino, Ph.D. to its Scientific Advisory Board.

RoslinCT and Lykan Bioscience, leaders in ground-breaking Contract Development and Manufacturing for cell therapies, are delighted to announce that following a successful inspection at their Edinburgh, UK facility, from the Medicines and Healthcare products Regulatory Agency (MHRA), a Manufacturer’s Authorisation Licence (MIA) for commercial manufacturing of cell therapy products has been granted.

Lykan Bioscience and RoslinCT, a leader in Contract Development and Manufacturing for cell therapies, announced the formation of its inaugural Scientific Advisory Board (SAB).